WuXi AppTec

WuXi AppTec is a Shanghai-headquartered contract research, development and manufacturing organization, commonly described as a CRDMO. It provides outsourced scientific and manufacturing services to pharmaceutical, biotechnology and healthcare companies rather than primarily selling medicines under its own consumer-facing product brands. Its platform covers small-molecule drug discovery and development, chemistry manufacturing, biology discovery, preclinical testing, clinical research, analytical and bioanalytical services, pharmaceutical manufacturing, and selected advanced-therapy capabilities. The company operates through a network spanning China, North America and Europe, with additional activities in Singapore and other Asian markets. The company was founded in Shanghai in December 2000 by organic chemist Ge Li and three co-founders. It began as WuXi PharmaTech with a relatively small chemistry laboratory and an emphasis on helping pharmaceutical innovators perform discovery chemistry more efficiently. Its business model was built around an open-access platform: customers could use WuXi's scientists, laboratories, development systems and manufacturing capacity without having to build all of those capabilities internally. The model was intended to reduce development costs, shorten project timelines and allow biotechnology companies to advance candidates through increasingly complex stages of development. WuXi's international profile grew rapidly during the 2000s. It opened chemistry facilities in Tianjin, completed a U.S. initial public offering in 2007 under the symbol WX, and acquired AppTec Laboratory Services in 2008. AppTec added expertise in biologics testing, medical-device testing and related laboratory services, and the combined company adopted the WuXi AppTec name. Subsequent expansion added toxicology, bioanalytical, pharmacokinetic, clinical-research, biologics and commercial-manufacturing capabilities. Acquisitions such as Abgent, MedKey, XenoBiotic Laboratories, Crelux, HD Biosciences and Pharmapace broadened the platform across biology, structure-based drug discovery, bioanalysis, clinical data and biometrics. The company was taken private in 2015 in a transaction reported at approximately $3.3 billion, after which it rebuilt its public-market presence in China. WuXi Biologics was separated and listed in Hong Kong in 2017. WuXi AppTec returned to public markets through a Shanghai listing in 2018 and subsequently completed a Hong Kong listing. This restructuring created a broader WuXi ecosystem while leaving WuXi AppTec focused on chemistry, preclinical, clinical, testing and manufacturing services. During the 2020s, WuXi AppTec invested in new modalities and geographically diversified manufacturing. WuXi STA expanded oligonucleotide and high-potency active-pharmaceutical-ingredient production, while the company acquired a Bristol Myers Squibb drug-product manufacturing site in Couvet, Switzerland, and acquired the United Kingdom cell- and-gene-therapy company OXGENE. It also announced facilities in Middletown, Delaware, and Singapore. Its service portfolio has consequently included small molecules, peptides, oligonucleotides, biologics-related activities, cell and gene therapy support, formulation and drug-product manufacturing, clinical research, and medical-device testing. The company became a major subject of U.S. policy and national-security debate in 2024 and 2025. Members of Congress proposed the BIOSECURE Act, which identified WuXi AppTec and other Chinese biotechnology companies as potential companies of concern for certain U.S. government-related contracts and funding. U.S. officials and media reports raised allegations concerning data security, intellectual property and possible links to Chinese state or military institutions; WuXi AppTec denied unauthorized transfers of client information, denied affiliation with the Chinese Communist Party or People's Liberation Army, and said it complies wi…

WuXi AppTec was established in Shanghai in December 2000 by organic chemist Ge Li and three co-founders. Its original name was WuXi PharmaTech, and its initial activity centered on chemistry services for pharmaceutical research. The founders created the company around an outsourced, open-access model that allowed pharmaceutical and biotechnology customers to use specialized research infrastructure without independently building every laboratory and technical function required for drug discovery. The company expanded its chemistry footprint during the 2000s. It opened facilities in Tianjin and broadened its scientific service offering into bioanalytical work. In 2007, WuXi PharmaTech completed an initial public offering in the United States, with its shares trading on the New York Stock Exchange under the symbol WX. In 2008, it acquired AppTec Laboratory Services, a U.S. company with capabilities in biologics testing, medical-device testing and related laboratory services. The acquisition materially widened WuXi's platform, and the company adopted the WuXi AppTec name. During the early 2010s, WuXi added toxicology, pharmaceutical manufacturing and biologics capabilities. WuXi STA opened a large-scale manufacturing facility in Jinshan in 2010. In 2011, WuXi developed biologics discovery, development and manufacturing operations in Shanghai and Wuxi, acquired MedKey and acquired San Diego-based Abgent. In 2012, the company opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi. It also entered a joint venture with MedImmune, AstraZeneca's biologics arm, to co-develop an anti-IL-6 antibody for the Chinese market. In 2013, WuXi formed a joint venture with PRA International to build a clinical research business in China. In 2014, WuXi opened a biologics biosafety-testing facility in Suzhou and acquired XenoBiotic Laboratories, adding bioanalytical, drug-metabolism and pharmacokinetic services. It also expanded into genomics and bioinformatics through WuXi NextCODE after acquiring NextCODE Health. That business later separated from WuXi AppTec in 2019 and became Genuity Science. A major ownership and capital-markets transition occurred in 2015. WuXi AppTec was taken private in a transaction reported at approximately $3.3 billion, and the company left the U.S. public markets. It subsequently continued expanding internationally. WuXi STA opened a Changzhou campus and operations in San Diego in 2016, while WuXi AppTec acquired German structure-based drug-discovery provider Crelux. In 2017, it acquired HD Biosciences, a biology-focused preclinical drug-discovery CRO. WuXi Biologics was spun off and listed in Hong Kong in 2017. WuXi AppTec itself returned to public markets through a Shanghai IPO in 2018 and later completed a Hong Kong listing. The platform continued to diversify from 2019 onward. WuXi AppTec acquired Pharmapace in 2019, strengthening biometrics and clinical-data capabilities. WuXi STA opened an oligonucleotide active-pharmaceutical-ingredient facility in Changzhou in 2020. In 2021, WuXi acquired OXGENE, a U.K. cell- and gene-therapy research and development company, and acquired a Bristol Myers Squibb drug-product manufacturing facility in Couvet, Switzerland. The company also announced a new campus in Middletown, Delaware. In 2022, it announced a major Singapore expansion and opened a high-potency API facility in Jiangsu. WuXi AppTec's global position became politically contentious in the United States in 2024. Proposed legislation known as the BIOSECURE Act sought to restrict federal contracts and certain federally connected business involving biotechnology companies identified as security concerns, including WuXi AppTec. Congressional letters and media reports raised questions about the company's data handling, intellectual-property controls and possible relationship with Chinese government or military institutions. WuXi denied affiliation with the Chinese Communist Party or People's Liberation Army, rejected allegations of unauthorized data transfers, and emphasized its compliance and information-security procedures. The company also engaged in U.S. advocacy and lobbying in response to the legislative campaign. The regulatory environment contributed to a strategic refocusing. In December 2024, WuXi AppTec announced the sale of WuXi Advanced Therapies and OXGENE to Altaris. The transaction was completed in March 2025. In January 2025, the company announced the sale of its U.S. medical-device testing operations to NAMSA; NAMSA completed the transaction on February 28, 2025. WuXi described both actions as portfolio optimization designed to concentrate resources on its core pharmaceutical CRDMO model. In 2025 and 2026, WuXi AppTec continued reporting growth in its continuing operations while facing increased U.S. scrutiny. The company reported record 2025 performance and highlighted growth in chemistry CRDMO services, peptides, oligonucleotides and late-stage development work. In June 2026, the U.S. Department of Defense placed WuXi AppTec on the Section 1260H list of Chinese military companies operating in the United States. WuXi disputed the designation and filed a federal lawsuit on June 11, 2026. As of August 27, 2026, the company remains active, publicly listed and headquartered in Shanghai, with operations across Asia, Europe and North America.

1. 2026Section 1260H designation challenged

   WuXi AppTec challenged the U.S. Department of Defense designation of the company as a Chinese military company in federal court.

   Source
2. 2025Divestiture of U.S. medical-device testing operations

   WuXi sold its U.S. medical-device testing business to NAMSA, which completed the acquisition on February 28, 2025.

   Source
3. 2025Advanced Therapies divestiture completed

   Altaris completed its acquisition of WuXi Advanced Therapies and OXGENE on March 7, 2025.

   Source
4. 2024Singapore site groundbreaking

   WuXi AppTec broke ground on a new Singapore site intended to expand API manufacturing capabilities.

   Source
5. 2024BIOSECURE Act controversy

   WuXi AppTec became a central target of U.S. legislative and national-security scrutiny concerning Chinese biotechnology companies.

   Source
6. 2022Delaware and Singapore expansion plans

   The company announced a Middletown, Delaware development site and a major Singapore manufacturing expansion.

   Source
7. 2021OXGENE acquisition and Swiss manufacturing expansion

   WuXi acquired OXGENE and expanded into large-scale drug-product manufacturing through the Couvet, Switzerland site.

   Source
8. 2020Oligonucleotide manufacturing expansion

   WuXi STA opened an oligonucleotide API plant in Changzhou.

   Source
9. 2019Pharmapace acquisition

   The acquisition strengthened biometrics, clinical-data and statistical services.

   Source
10. 2018Shanghai and Hong Kong relistings

    WuXi AppTec completed a Shanghai IPO and subsequently listed shares in Hong Kong.

    Source
11. 2017WuXi Biologics spun off and listed

    WuXi's biologics division became a separately listed Hong Kong company.

    Source
12. 2016Crelux acquisition

    WuXi acquired the German structure-based drug-discovery provider Crelux.

    Source
13. 2015Take-private transaction

    WuXi AppTec completed a cash acquisition by New WuXi Life Science Limited and left U.S. public markets.

    Source
14. 2014XenoBiotic Laboratories acquisition

    The acquisition expanded bioanalytical, drug-metabolism and pharmacokinetic services.

    Source
15. 2011Expansion into biologics and additional acquisitions

    WuXi began biologics discovery, development and manufacturing operations and acquired MedKey and Abgent.

    Source
16. 2010WuXi STA opens Jinshan manufacturing facility

    The subsidiary expanded WuXi's large-scale pharmaceutical manufacturing capacity.

    Source
17. 2008Acquisition of AppTec Laboratory Services

    The acquisition added U.S. biologics, medical-device and laboratory-testing capabilities, and the company adopted the WuXi AppTec name.

    Source
18. 2007U.S. initial public offering

    WuXi PharmaTech listed shares on the New York Stock Exchange under the symbol WX.

    Source
19. 2000WuXi PharmaTech founded in Shanghai

    Ge Li and three co-founders established the company in Shanghai as a chemistry-focused pharmaceutical services provider.

    Source

An integrated, open-access global CRDMO platform designed to let pharmaceutical and biotechnology customers outsource discovery, development, testing and manufacturing activities across the drug-development lifecycle.

• WuXi ChemistrySmall-molecule CRDMO2000

  WuXi Chemistry provides discovery chemistry, process research, scale-up, development and commercial manufacturing for small-molecule medicines. Its model links early research with development and manufacturing so that projects can move through the pipeline using a common technical platform. The business also supports newer chemistry modalities such as peptides and oligonucleotides, with capabilities extending from laboratory synthesis to larger-scale production.

• WuXi STAPharmaceutical development and manufacturing2010

  WuXi STA is the company's pharmaceutical development and manufacturing business. It supports active pharmaceutical ingredients, drug products, process development, scale-up, technology transfer and commercial supply. Its network includes capabilities for small molecules, peptides, oligonucleotides, high-potency compounds and solid-dose products, with manufacturing sites in China and Europe.

• WuXi BiologyBiology discovery and preclinical research2011

  WuXi Biology provides biology discovery and preclinical services used to identify and characterize drug candidates. Activities include assay development, screening, pharmacology, translational research and related laboratory work. The business grew through internal expansion and acquisitions including Abgent, HD Biosciences and other specialist platforms.

• WuXi TestingSafety, analytical and bioanalytical testing2005

  WuXi Testing provides toxicology, biosafety, analytical, bioanalytical, drug-metabolism and pharmacokinetic services. The platform supports regulatory submissions and development decisions by generating data on a candidate's identity, purity, exposure, safety and biological behavior. It serves pharmaceutical, biotechnology and selected healthcare customers.

• WuXi ClinicalClinical research and clinical data services2013

  WuXi Clinical provides clinical research, clinical operations, biometrics, data management and related development services. Its capabilities were expanded through the MedKey joint venture and the Pharmapace acquisition. The business helps customers plan and execute clinical programs and organize the data required for regulatory and development decisions.

• WuXi Advanced TherapiesCell and gene therapy services2021

  WuXi Advanced Therapies was a contract testing, development and manufacturing platform for cell, gene and other advanced biopharmaceutical therapies. It combined testing, process development, manufacturing and commercialization support, and incorporated OXGENE's technologies for viral-vector and gene-therapy development. WuXi AppTec sold the U.S. and U.K. operations to Altaris in 2025.

• Medical-device testing operationsMedical-device testing2008

  WuXi AppTec's former U.S. medical-device testing operations provided biological safety, microbiology, extractables and leachables and related laboratory services. The facilities in Minnesota and Georgia were sold to NAMSA in 2025, ending WuXi AppTec's direct ownership of those U.S. operations.

• 2024U.S. BIOSECURE Act advocacy campaign

  United States

  After WuXi AppTec was identified in proposed U.S. biotechnology-security legislation, the company launched a public affairs and lobbying response. The campaign emphasized the company's independence from the Chinese Communist Party and People's Liberation Army, its data-security controls and its compliance with U.S. law.

  Outcome. The campaign did not prevent continued congressional scrutiny. WuXi later pursued portfolio divestitures and challenged a 2026 Department of Defense designation in court.

  Source
• 2020COVID-19 business continuity and collaboration initiative

  Global

  During the COVID-19 outbreak, WuXi AppTec activated business-continuity measures, worked to protect employees and maintained support for customers' drug-discovery and development programs. The company also participated in international collaboration and hosted COVID-19-related forums.

  Outcome. The initiative was presented as a continuity and collaboration effort intended to keep life-science development programs moving during the pandemic.

  Source

• 2026Challenge Department of Defense designationOther

  WuXi AppTec disputed its inclusion on the U.S. Department of Defense Section 1260H list.

  What changed. The company filed a complaint in the U.S. District Court for the District of Columbia on June 11, 2026.

  Aftermath. The litigation remained an active component of WuXi's response to U.S. national-security restrictions as of August 27, 2026.

  Source
• 2025Sell U.S. medical-device testing operations to NAMSAM&A

  WuXi AppTec described the transaction as portfolio optimization and a way to focus investment on its core pharmaceutical CRDMO platform.

  What changed. The company sold its Minnesota and Georgia medical-device testing facilities to NAMSA; completion occurred on February 28, 2025.

  Aftermath. NAMSA integrated the facilities into its medical-device testing network, while WuXi retained its pharmaceutical research, development and manufacturing operations.

  Source
• 2024Refocus portfolio amid U.S. regulatory pressureStrategy

  Proposed U.S. biotechnology-security restrictions increased uncertainty around WuXi's U.S. and European assets and customer relationships.

  What changed. WuXi AppTec agreed to sell WuXi Advanced Therapies and OXGENE to Altaris and later agreed to sell its U.S. medical-device testing operations to NAMSA.

  Aftermath. The divestitures reduced exposure to selected non-core activities and concentrated the company more tightly on pharmaceutical CRDMO services.

  Source
• 2021Acquire OXGENEM&A

  WuXi AppTec wanted to strengthen its cell- and gene-therapy platform with scalable viral-vector and gene-engineering technologies.

  What changed. WuXi completed the acquisition of OXGENE, a U.K. contract research and development company, and placed it within WuXi Advanced Therapies.

  Aftermath. The acquisition expanded WuXi's European advanced-therapy footprint and added technologies for AAV and lentiviral manufacturing.

  Source
• 2021Acquire Couvet drug-product manufacturing facilityM&A

  WuXi sought European drug-product manufacturing capacity and geographic diversification.

  What changed. WuXi STA acquired a Bristol Myers Squibb manufacturing facility in Couvet, Switzerland.

  Aftermath. The site became an important European manufacturing location for drug products and expanded WuXi STA's international supply network.

  Source
• 2018Return to public marketsOther

  Following the 2015 take-private transaction, WuXi AppTec sought renewed access to public equity capital in China and Hong Kong.

  What changed. The company completed a Shanghai IPO and subsequently listed shares in Hong Kong.

  Aftermath. WuXi AppTec became a dual-market listed company and was later included in major Hong Kong market indexes.

  IPO proceeds. Private company after 2015 take-private → Shanghai IPO raising more than $900 million, followed by Hong Kong listing (2018)

  Source
• 2017Spin off WuXi BiologicsStrategy

  The biologics business had developed into a substantial standalone platform with its own growth and capital requirements.

  What changed. WuXi Biologics was separated from WuXi AppTec and listed on the Hong Kong Stock Exchange.

  Aftermath. The transaction created a separately listed WuXi-related biologics company while WuXi AppTec retained its core chemistry, testing, clinical and manufacturing businesses.

  Source
• 2015Take-private transactionM&A

  WuXi AppTec and other Chinese companies sought valuations closer to their domestic market after trading in the United States.

  What changed. New WuXi Life Science Limited acquired WuXi AppTec in a cash transaction reported at approximately $3.3 billion, and the company was delisted from U.S. exchanges.

  Aftermath. The private ownership period preceded the company's return to public markets in Shanghai and Hong Kong in 2018.

  Transaction value. Publicly traded on the New York Stock Exchange → Acquired by New WuXi Life Science Limited (2015)

  Source
• 2008Acquire AppTec Laboratory ServicesM&A

  WuXi PharmaTech sought to broaden its chemistry-centered platform with U.S. capabilities in biologics testing, medical-device testing and laboratory services.

  What changed. The company acquired AppTec Laboratory Services and changed its English name to WuXi AppTec.

  Aftermath. The transaction created a more comprehensive international research and testing platform.

  Source

• 2026Section 1260H Chinese military-company designationControversy

  The U.S. Department of Defense included WuXi AppTec on its Section 1260H list. WuXi described the designation as incorrect and unsupported, and filed a federal lawsuit seeking to overturn it.

  Source
• 2024U.S. national-security and intellectual-property allegationsControversy

  WuXi AppTec faced allegations in U.S. political and media discussions that it had relationships with Chinese state or military institutions and that U.S. client intellectual property or data may have been transferred to Chinese authorities without consent. WuXi denied unauthorized transfers, denied affiliation with the Chinese Communist Party or People's Liberation Army, and said it complies with U.S. law.

  Source

• 2026WuXi AppTec reports record performance for 2025

  WuXi AppTec reported strong 2025 growth in revenue, profit and cash flow, with continuing-operations backlog reaching RMB 58.0 billion according to the company's March 2026 announcement.

  Other
  Source
• 2025WuXi AppTec agrees to sell U.S. medical-device testing operations to NAMSA

  The company agreed to sell its medical-device testing facilities in Minnesota and Georgia to NAMSA as part of a portfolio optimization intended to focus investment on its core pharmaceutical CRDMO activities.

  M&A
  Source
• 2025NAMSA completes acquisition of WuXi AppTec U.S. medical-device testing business

  NAMSA completed the acquisition on February 28, 2025, bringing the former WuXi facilities and personnel into its medical-device testing platform.

  M&A
  Source
• 2025Altaris completes acquisition of WuXi Advanced Therapies and OXGENE

  Altaris completed the acquisition of the Advanced Therapies U.S. and OXGENE operations on March 7, 2025. The divested business subsequently operated under the Minaris Advanced Therapies identity.

  M&A
  Source
• 2024WuXi AppTec announces sale of WuXi Advanced Therapies to Altaris

  WuXi AppTec announced a definitive agreement to sell the U.S. and U.K. operations of its cell- and gene-therapy unit, WuXi Advanced Therapies, to healthcare investment firm Altaris.

  M&A
  Source

1. WuXi AppTec
2. About WuXi AppTec
3. WuXi AppTec History and Milestones
4. WuXi AppTec Leadership
5. WuXi AppTec completes acquisition of OXGENE
6. WuXi AppTec agrees to sell U.S. medical-device testing operations to NAMSA
7. NAMSA completes acquisition of WuXi AppTec U.S. medical-device testing business
8. Altaris completes acquisition of WuXi Advanced Therapies and OXGENE
9. WuXi AppTec 2025 performance announcement
10. WuXi AppTec legal challenge to Section 1260H designation
11. Reuters report on U.S. client data allegations
12. U.S. Department of Defense Section 1260H information
13. COVID-19 business continuity and collaboration initiative
14. U.S. BIOSECURE Act advocacy campaign
15. Refocus portfolio amid U.S. regulatory pressure